Health care reform has generated interest in identifying strategies to decrease health care costs without depriving patients of the health benefits of evidence-based therapies and generic formulations of drugs.
1-3 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial recently showed that fenofibrate plus statins in patients with type 2 diabetes did not reduce cardiovascular events more than use of statins alone.
4 The only other fenofibrate study, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), also failed to show reduced cardiovascular morbidity and mortality.
5 These negative studies raise questions about a medication with more than $1 billion in sales in the United States.
6